|
US6544769B1
(en)
*
|
1996-12-13 |
2003-04-08 |
Schering Corporation |
Compostions comprising viruses and methods for concentrating virus preparations
|
|
US20080261289A1
(en)
*
|
1996-12-13 |
2008-10-23 |
Schering-Plough Corporation |
Compositions comprising viruses and methods for concentrating virus preparations
|
|
US6759050B1
(en)
|
1998-12-03 |
2004-07-06 |
Avigen, Inc. |
Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
|
|
ES2185417T3
(es)
*
|
1998-12-03 |
2003-04-16 |
Avigen Inc |
Excipientes para usar en formulaciones farmaceuticas de virus adeno-asociados, y formulaciones farmaceuticas producidas con ellos.
|
|
US6225289B1
(en)
*
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
|
FR2791999B1
(fr)
*
|
1999-04-09 |
2001-09-07 |
Aventis Pharma Sa |
Composition destinee a la conservation d'adenovirus recombinants infectieux
|
|
IL145447A0
(en)
|
1999-04-09 |
2002-06-30 |
Aventis Pharma Sa |
Composition for the preservation of infectious recombinant adenoviruses
|
|
US7456009B2
(en)
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
CA2399321C
(en)
|
2000-03-07 |
2013-04-30 |
Robert K. Evans |
Adenovirus formulations
|
|
EP1284287A4
(en)
*
|
2000-05-10 |
2004-10-13 |
Mitsubishi Pharma Corp |
METHOD FOR PRODUCING A VIRUS VECTOR
|
|
WO2003049764A1
(en)
|
2001-12-12 |
2003-06-19 |
Fh Faulding & Co Limited |
Composition for viral preservation
|
|
EP1465664A1
(en)
*
|
2002-01-18 |
2004-10-13 |
Schering Aktiengesellschaft |
Stabilized formulations of adenovirus
|
|
KR100507794B1
(ko)
*
|
2003-02-11 |
2005-08-17 |
한미약품 주식회사 |
고농도 레트로 바이러스 현탁액 제조 방법
|
|
US20070148765A1
(en)
*
|
2003-11-19 |
2007-06-28 |
Evans Robert K |
Preservative-containing virus formulations
|
|
EP1780269B1
(en)
*
|
2004-02-23 |
2009-07-08 |
Crucell Holland B.V. |
Virus purification methods
|
|
GB0502661D0
(en)
*
|
2005-02-09 |
2005-03-16 |
Stabilitech Ltd |
A desiccated product
|
|
DK1869171T4
(en)
*
|
2005-04-11 |
2016-01-18 |
Crucell Holland Bv |
Virus cleaning using ultrafiltration
|
|
CN1961961B
(zh)
*
|
2005-11-11 |
2010-05-26 |
深圳市源兴生物医药科技有限公司 |
一种药物制剂及其制备方法
|
|
WO2010060719A1
(en)
|
2008-11-03 |
2010-06-03 |
Crucell Holland B.V. |
Method for the production of adenoviral vectors
|
|
DK2536829T3
(en)
|
2010-02-15 |
2016-07-04 |
Crucell Holland Bv |
A process for the production of Ad26-adenovirus vectors
|
|
CN103118702A
(zh)
|
2010-09-20 |
2013-05-22 |
克鲁塞尔荷兰公司 |
活动性结核病的治疗性接种
|
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
|
EA201390810A1
(ru)
|
2010-12-02 |
2013-09-30 |
Онколитикс Байотек Инк. |
Жидкие вирусные составы
|
|
EA201390812A1
(ru)
|
2010-12-02 |
2013-11-29 |
Онколитикс Байотек Инк. |
Лиофилизированные вирусные составы
|
|
CA2864956C
(en)
|
2012-03-12 |
2021-11-09 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
KR102023791B1
(ko)
|
2012-03-22 |
2019-09-23 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
TWI638829B
(zh)
|
2012-07-10 |
2018-10-21 |
法商傳斯堅公司 |
分枝桿菌抗原疫苗
|
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
|
US10899800B2
(en)
|
2013-04-25 |
2021-01-26 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
PE20160045A1
(es)
|
2013-06-17 |
2016-02-18 |
Crucell Holland Bv |
Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
|
|
MX2016009072A
(es)
|
2014-01-09 |
2017-05-08 |
Transgene Sa |
Fusion de antigenos micobacterianos heterooligomericos.
|
|
US9721484B2
(en)
|
2014-06-23 |
2017-08-01 |
Humanetics Innovative Solutions, Inc. |
Shoulder kit assembly for crash test dummy
|
|
WO2016008976A1
(en)
|
2014-07-16 |
2016-01-21 |
Transgene Sa |
Oncolytic virus for expression of immune checkpoint modulators
|
|
US10008130B2
(en)
|
2014-09-17 |
2018-06-26 |
Humanetics Innovative Solutions, Inc. |
Omni-directional shoulder assembly for crash test dummy
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
KR102638978B1
(ko)
|
2015-07-07 |
2024-02-22 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
|
KR20180026734A
(ko)
|
2015-07-07 |
2018-03-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 가용성 융합-전 rsv f 폴리펩티드
|
|
PH12022552125A1
(en)
|
2016-04-05 |
2023-04-12 |
Janssen Vaccines & Prevention Bv |
Stabilized soluble pre-fusion rsv f proteins
|
|
EA201892250A1
(ru)
|
2016-04-05 |
2019-03-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцина против rsv
|
|
CN109154000B
(zh)
|
2016-05-12 |
2022-07-05 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
|
EA039124B1
(ru)
|
2016-05-30 |
2021-12-08 |
Янссен Вэксинс Энд Превеншн Б.В. |
Стабилизированные f-белки rsv до слияния
|
|
MX393584B
(es)
|
2016-06-20 |
2025-03-21 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado.
|
|
EP3484506A1
(en)
|
2016-07-14 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Hpv vaccines
|
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
JP7110203B2
(ja)
|
2016-12-28 |
2022-08-01 |
トランジェーヌ |
腫瘍溶解性ウイルスおよび治療用分子
|
|
SG11201906271QA
(en)
|
2017-02-09 |
2019-08-27 |
Janssen Vaccines & Prevention Bv |
Potent and short promoter for expression of heterologous genes
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
AU2018267971A1
(en)
|
2017-05-17 |
2019-11-07 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
JP2020533367A
(ja)
|
2017-09-15 |
2020-11-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
Ｒｓｖに対する免疫の安全な誘導方法
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
WO2020090871A1
(ja)
|
2018-10-30 |
2020-05-07 |
国立大学法人東京大学 |
がん治療のための腫瘍溶解性ウイルス
|
|
MX2021005607A
(es)
|
2018-11-13 |
2021-06-30 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del vrs estabilizadas.
|
|
EP4097122A4
(en)
|
2020-01-31 |
2024-07-17 |
Beth Israel Deaconess Medical Center, Inc. |
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
|
|
WO2021186246A1
(en)
|
2020-03-19 |
2021-09-23 |
Trizell Ltd. |
Temperature-responsive virus storage system
|
|
TW202217002A
(zh)
|
2020-07-13 |
2022-05-01 |
法商傳斯堅公司 |
免疫抑制之治療
|
|
AU2022214006A1
(en)
|
2021-02-01 |
2023-09-21 |
St Phi Therapeutics Co., Ltd. |
Targeted protein degradation system and use thereof
|
|
EP4294436A1
(en)
|
2021-02-19 |
2023-12-27 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb fantigens
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023025899A2
(en)
|
2021-08-26 |
2023-03-02 |
Transgene |
Delivery system for targeting genes of the interferon pathway
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
CN119654339A
(zh)
|
2022-07-01 |
2025-03-18 |
特兰斯吉恩股份有限公司 |
包含表面活性蛋白-d和tnfsf成员的融合蛋白
|
|
TW202413636A
(zh)
|
2022-08-18 |
2024-04-01 |
法商傳斯堅公司 |
嵌合痘病毒
|